



Life Settlement Assets PLC – Ordinary Share A

Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Commentary

The life settlements market seems to have stabilized and embarked on a steady growth trajectory in the last two years, according to a new study by Conning. The second consecutive year of growth in the amount of face value settled may indicate a renewed interest in life settlements by investors. Investor interest reflects a combination of a prolonged low interest rate environment, continued investment allocations to non-correlating alternative asset classes, and the stability of the life settlement landscape. This stability results from greater investor understanding of the asset class and associated risks, a more favorable tax environment, and demographics trends driving a growing supply of policies that could be settled. Acheron Capital view remains that the current medical underwriting will result in significant market upheavals which, together with recession triggered liquidity pull out, will affect the asset class. Because of its pricing and management, our portfolios should be largely shielded from these forthcoming adverse effects.

The Share Class is reporting a performance of -1.63% for the month of October. Seven HIV maturities have been registered, contributing a total Death Benefit of \$222k. One small maturity was registered in the elderly segment. Currently, the HIV segment has still performed above expectations by 15%. However, the elderly segment, despite the advanced ages, still underperforms. On a weighted basis, the life settlement part of the portfolio now has an average age approaching 90.


Investment Terms	Estimated NAV (USD)	NAV/Share
1.5% Management Fee	89,228,765.22	1.9634


Number Of Policies	Death Benefits (USD)	Matured Policies	YTD*	Maturities YTD (USD)*
4 633	464 499 646	98		11 918 116
Trust Investment Manager	Acheron Capital Ltd.	Company Secretary	Maitland Administration Services Limited	
Administrator	Compagnie Européenne de Révision	ISIN Ticker	GB00BF1Q4B05 LSAA	
Auditor	Grant Thornton UK LLP	Info	-	heroncapital.com 258 5990















Maturities Since Inception



(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.
(2)Distribution by issue dates reflects the time since the life insurance policy was issued.
Source of Data: Acheron Capital Ltd unless otherwise stated.

October 2018






\$13.4M

\$12.1M

\$11.2M



Maturities October 2018


Premiums Situation (US\$)⁽¹⁾

Servicers Premiums

Projection as of Beginning

Mortality Adjusted Premiums

Number of policies matured in October 2018	8
Corresponding number of insured	5
Total death benefit in October 2018(US\$)	234 476
Valuation of Matured policies in Book (US\$)	51 855



Top 10 Coverage

Projection Beginning 2018 Estimated COI Net of Mortality Beginning 2018

2018

Cash Situation (US\$)⁽¹⁾

	Total Face	Age		Cash at hand and similar	\$ 10.0M
Face (millions)	(millions)	(ALB)	Expiration Age*	Gross Cash in Policies ⁽²⁾	\$ 41.7M
8.6/2.4/1.0	12.0	99	101/121/101	(estimated as of end 2017)	φ 41.7 W
10.2	10.2	98	100		
3.1/3.0/2.0	8.1	98	115/120/120	Loan on Cash in Policies	\$ 22.2M
3.8	3.8	93	100	(estimated as of end 2017)	
1.9/1.4	3.3	94	100/100	Net Cash in Policies ⁽²⁾	\$ 19.5M
2.8	2.8	77	100	(estimated as of end 2017)	
1.2/0.9/0.6	2.7	75	121/100/100	Maturities to be received	\$ 4.0M
1.2/0.8/0.4/0.1/0.1/0.1	2.7	90	100/100/100/95/100/115		
2.7	2.7	93	100		
1.3/1.0	2.3	94	100/115		

(1) Figures as provided by third parties

Insured

1

3 4 5

6 7

8 9 10

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Cash for fractional policies and ABC policies not included. Surrender charge included. *In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.